ESMO - Eur. Oncology· @myESMO · X·· 23 hours agoScore70
Body
#ESMO26: Pembrolizumab plus chemotherapy reduced the risk of PFS by 26% in PD-L1-positive, HR-positive #AdvancedBreastCancer after failure on endocrine therapy in the phase III KEYNOTE-B49
🔗 https://ow.ly/5NoZ50ZZjCH
#ClinicalTrial #BreastCancer #InsightsbyESMO
@PTarantinoMD
302 views · 1 like · 0 reposts · 0 replies
Conference abstracts
LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.orgSource: ESMO - Eur. Oncology · x.com